137 related articles for article (PubMed ID: 1761078)
1. Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man.
Hasselström J; Enquist M; Hermansson J; Dahlqvist R
Eur J Clin Pharmacol; 1991; 41(5):481-4. PubMed ID: 1761078
[TBL] [Abstract][Full Text] [Related]
2. Human pharmacokinetics and metabolism of disopyramide enantiomers.
Le Corre P; Gibassier D; Sado P; Le Verge R
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():233-7. PubMed ID: 1820885
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
Le Corre P; Gibassier D; Sado P; Le Verge R
Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective pharmacokinetics of disopyramide enantiomers in man.
Lima JJ; Boudoulas H; Shields BJ
Drug Metab Dispos; 1985; 13(5):572-7. PubMed ID: 2865105
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography.
Takahashi H; Tamura A; Ogata H; Masuhara K
J Chromatogr; 1990 Aug; 529(2):347-58. PubMed ID: 2229254
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective disposition and metabolism of disopyramide in pediatric patients.
Echizen H; Takahashi H; Nakamura H; Ochiai K; Chiba K; Koike K; Ogata H; Ishizaki T
J Pharmacol Exp Ther; 1991 Dec; 259(3):953-60. PubMed ID: 1762088
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective pharmacokinetics and pharmacodynamics of disopyramide and its metabolite in rabbits.
Horikawa M; Yasumuro M; Kanno M; Hanada K; Hashiguchi M; Ogata H
J Pharm Pharmacol; 2001 Dec; 53(12):1621-8. PubMed ID: 11804392
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine.
Bonde J; Pedersen LE; Nygaard E; Ramsing T; Angelo HR; Kampmann JP
Br J Clin Pharmacol; 1991 Jun; 31(6):708-10. PubMed ID: 1867965
[TBL] [Abstract][Full Text] [Related]
9. In vivo interaction of the enantiomers of disopyramide in human subjects.
Giacomini KM; Nelson WL; Pershe RA; Valdivieso L; Turner-Tamiyasu K; Blaschke TF
J Pharmacokinet Biopharm; 1986 Aug; 14(4):335-56. PubMed ID: 3772736
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients.
Aso R; Ohashi K; Katoh T; Ogata H
Int J Clin Pharmacol Res; 2001; 21(3-4):137-46. PubMed ID: 12067143
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective biliary elimination of disopyramide and mono-N-desisopropyldisopyramide in humans.
le Corre P; Malledant Y; Chevanne F; Sado P; le Verge R
Chirality; 1992; 4(2):80-3. PubMed ID: 1616827
[TBL] [Abstract][Full Text] [Related]
12. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
[TBL] [Abstract][Full Text] [Related]
13. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.
Cunningham JL; Shen DD; Shudo I; Azarnoff DL
Clin Pharmacokinet; 1977; 2(5):373-83. PubMed ID: 21054
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous determination of disopyramide and mono-N-dealkyldisopyramide enantiomers in plasma and urine by use of a chiral cellulose-derivative column.
Echizen H; Ochiai K; Kato Y; Chiba K; Ishizaki T
Clin Chem; 1990 Jul; 36(7):1300-4. PubMed ID: 2372941
[TBL] [Abstract][Full Text] [Related]
15. Antiarrhythmic activity and unbound concentrations of disopyramide enantiomers in patients.
Lima JJ; Wenzke SC; Boudoulas H; Schaal SF
Ther Drug Monit; 1990 Jan; 12(1):23-8. PubMed ID: 2305417
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of levorotatory and racemic disopyramide, at steady state, following oral administration in patients with ventricular arrhythmias.
Le Corre P; Gibassier D; Descaves C; Sado P; Daubert JC; Le Verge R
J Clin Pharmacol; 1989 Dec; 29(12):1089-96. PubMed ID: 2482304
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of disopyramide in normal volunteers using unbound concentration.
Braun J; Sörgel F; Gluth WP; Oie S
Eur J Clin Pharmacol; 1987; 32(6):625-9. PubMed ID: 3653232
[TBL] [Abstract][Full Text] [Related]
18. Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects.
Chiang WT; von Bahr C; Calissendorff B; Dahlqvist R; Emilsson H; Magnusson A; Schenck-Gustafsson K
Clin Pharmacol Ther; 1985 Jul; 38(1):37-44. PubMed ID: 4006374
[TBL] [Abstract][Full Text] [Related]
19. Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline.
Davies BJ; Herbert MK; Coller JK; Somogyi AA; Milne RW; Sallustio BC
Br J Clin Pharmacol; 2008 Mar; 65(3):347-54. PubMed ID: 17875193
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of disopyramide in the dog. Importance of mono-N-dealkylated metabolite kinetics in assessing pharmacokinetic modeling of the parent drug.
Cook CS; Gwilt PR; Kowalski K; Gupta S; Oppermann J; Karim A
Drug Metab Dispos; 1990; 18(1):42-9. PubMed ID: 1970776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
